Optical News

NASHVILLE, Tenn.--(BUSINESS WIRE)--Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, today announced the commercial launch of Mosaic Reporting™, a new class of AI-native radiology reporting solution available as part of MosaicOS™. Mosaic Reporting is already deployed to thousands of radiologists through Radiology Partners-affiliated practices, giving Mosaic a scaled real-world environment to refine and expand the platform. Powered by foundation models developed by...

MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé advances Phase 3 study of Cenegermin-bkbj (a rhNGF) for PCED, a rare condition with high unmet clinical need....

SALT LAKE CITY--(BUSINESS WIRE)--Eyebot and The Framery at 1-800 Contacts today announced a new partnership kicking off in The Framery’s hometown of Salt Lake City, Utah. Beginning June 3, Eyebot Kiosks will be open at Layton Hills Mall in Layton, Utah and Valley Fair Mall in West Valley City, Utah, giving visitors a convenient way to complete a vision test, receive a doctor-reviewed glasses prescription, and shop for eyewear from The Framery. Eyebot was built to make routine prescription updat...

CORVALLIS, Ore.--(BUSINESS WIRE)--Phosio raised $4M to advance lightweight AR glasses with integrated displays using its proprietary thin-film platform and advanced materials....

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that 20-week study completion data from its head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD), will be presented at the Clinical Trials at the Summit (CTS) 2026, taking place from Jun...

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA's ODD provides incentives, including tax credits for clinical testing and up to seven years of U.S. market exclusi...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady’s conversation with Amin Makarem, Vice President, Biotechnology Equity Resea...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Triple Care Preservative Free eye drops, which provide instant, long-lasting relief for dry eyes without the use of preservatives and are packaged in a multi-dose bottle. Blink Triple Care Preservative Free is made with the same clinically proven formula as Blink Triple Care, helping red...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis launches Opuviz (aflibercept) in Europe....

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today announced that the company will present at the Eye Bank Association of America (EBAA) 2026 Annual Meeting, taking place in Indianapolis, Indiana, from June 3-6 and at the American-European Congress of Ophthalmic Surgery (AECOS) 2026 European Symposium, June 11-14 in Madrid, Spain. Aurion has been invited for the f...